Real-World Use of BTK Inhibitors in Chronic Lymphocytic Leukemia

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss the real-world use of BTK inhibitors for patients with chronic lymphocytic leukemia.

EP. 1: Factors for Selecting a BTK Inhibitor vs Other Regimens in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

EP. 2: Translating BTK Inhibitor Data into Clinical Decision-Making

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

EP. 3: The SEQUOIA Trial of Zanubrutinib vs BR in Previously Untreated CLL/SLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

EP. 4: Matching-Adjusted Indirect Comparisons of BTK Inhibitors in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss matching-adjusted indirect comparisons of BTK inhibitors in chronic lymphocytic leukemia.

EP. 5: Real-World Safety Data for BTK Inhibitors in CLL from EHA 2024

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.

EP. 6: Future Treatment Directions and Ongoing Trials in CLL

July 31st 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.